![[PDF]](/pb-assets/Icons/adobe-pdf-icon-1498649896243.png){kind=icon}
Abstract
Summary
We conducted a critical appraisal of published Phase 2 and 3 efficacy trials in relation to the prevention of cervical cancer in women. Our analysis shows the trials themselves generated significant uncertainties undermining claims of efficacy in these data. There were 12 randomised control trials (RCTs) of Cervarix and Gardasil. The trial populations did not reflect vaccination target groups due to differences in age and restrictive trial inclusion criteria. The use of composite and distant surrogate outcomes makes it impossible to determine effects on clinically significant outcomes. It is still uncertain whether human papillomavirus (HPV) vaccination prevents cervical cancer as trials were not designed to detect this outcome, which takes decades to develop. Although there is evidence that vaccination prevents cervical intraepithelial neoplasia grade 1 (CIN1) this is not a clinically important outcome (no treatment is given). Trials used composite surrogate outcomes which included CIN1. High efficacy against CIN1+ (CIN1, 2, 3 and adenocarcinoma in situ (AIS)) does not necessarily mean high efficacy against CIN3+ (CIN3 and AIS), which occurs much less frequently. There are too few data to clearly conclude that HPV vaccine prevents CIN3+. CIN in general is likely to have been overdiagnosed in the trials because cervical cytology was conducted at intervals of 6–12 months rather than at the normal screening interval of 36 months. This means that the trials may have overestimated the efficacy of the vaccine as some of the lesions would have regressed spontaneously. Many trials diagnosed persistent infection on the basis of frequent testing at short intervals, i.e. less than six months. There is uncertainty as to whether detected infections would clear or persist and lead to cervical changes.
Keywords
References
| 1. | Cancer Research UK. Cervical Cancer Mortality Statistics. See https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/cervical-cancer/mortality (2019, last checked 17 Apr 2019). Google Scholar |
| 2. | Bray, F, Ferlay, J, Soerjomataram, I, Siegel, RL, Torre, LA, Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424. Google Scholar | Crossref | Medline |
| 3. | Centers for Disease Control. HPV Vaccine Recommendations. See https://www.cdc.gov/vaccines/vpd/hpv/hcp/recommendations.html (2016, last checked 7 Oct 2017). Google Scholar |
| 4. | IARC . Biological Agents – A Review of Human Carcinogens – Human Papillomaviruses, Lyon: IARC, 2012. Google Scholar |
| 5. | Syrjanen, K, Hakama, M, Saarikoski, S, Vayrynen, M, Yliskoski, M, Syrjanen, S, et al. Prevalence, incidence, and estimated life-time risk of cervical human papillomavirus infections in a nonselected finnish female population. Sex Transm Dis 1990; 17: 15–19. Google Scholar | Crossref | Medline | ISI |
| 6. | Rodriguez, AC, Schiffman, M, Herrero, R, Wacholder, S, Hildesheim, A, Castle, PE, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008; 100: 513–517. Google Scholar | Crossref | Medline |
| 7. | WHO/ICO Information Centre on HPV and Cervical Cancer. HPV and cervical cancer in the 2007 report. Vaccine 2007; 25: C1–C230. Google Scholar |
| 8. | Couto, E, Saeterdal, I, Juvet, LK, Klemp, M. HPV catch-up vaccination of young women: a systematic review and meta-analysis. BMC Public Health 2014; 14: 867–867. Google Scholar | Crossref | Medline |
| 9. | Di Mario, S, Basevi, V, Lopalco, PL, Balduzzi, S, D’Amico, R, Magrini, N. Are the two human papillomavirus vaccines really similar? A systematic review of available evidence: efficacy of the two vaccines against HPV. J Immunol Res 2015; 2015: 435141–435141. Google Scholar | Crossref | Medline |
| 10. | Haug, CJ . Human papillomavirus vaccination – reasons for caution. N Engl J Med 2008; 359: 861–862. Google Scholar | Crossref | Medline | ISI |
| 11. | Tomljenovic, L, Spinosa, JP, Shaw, CA. Human papillomavirus (HPV) vaccines as an option for preventing cervical malignancies: (how) effective and safe? Curr Pharm Des 2013; 19: 1466–1487. Google Scholar | Medline | ISI |
| 12. | Ostor, AG . Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993; 12: 186–192. Google Scholar | Crossref | Medline | ISI |
| 13. | IARC . IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 90. Human Papillomaviruses, Lyon: IARC, 2007. Google Scholar |
| 14. | Carreon, JD, Sherman, ME, Guillen, D, Solomon, D, Herrero, R, Jeronimo, J, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol 2007; 26: 441–446. Google Scholar | Crossref | Medline | ISI |
| 15. | Peto, J, Gilham, C, Fletcher, O, Matthews, FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004; 364: 249–256. Google Scholar | Crossref | Medline | ISI |
| 16. | EMA. Gardasil: EPAR – Scientific Discussion. See http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000703/WC500021140.pdf (2006, last checked 28 Oct 2017). Google Scholar |
| 17. | Huh, WK, Joura, EA, Giuliano, AR, Iversen, OE, de Andrade, RP, Ault, KA, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet 2017; 390(10108): 2143–2159. Google Scholar | Crossref | Medline |
| 18. | Arbyn, M, Xu, L, Simoens, C, Martin-Hirsch, PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev 2018; 5: CD009069–CD009069. Google Scholar | Medline |
| 19. | Jorgensen, L, Gotzsche, PC, Jefferson, T. The Cochrane HPV vaccine review was incomplete and ignored important evidence of bias. BMJ Evid Based Med 2018; 23: 165–168. Google Scholar | Crossref | Medline |
| 20. | Harper, DM, Franco, EL, Wheeler, C, Ferris, DG, Jenkins, D, Schuind, A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757–1765. Google Scholar | Crossref | Medline | ISI |
| 21. | Harper, DM, Franco, EL, Wheeler, CM, Moscicki, AB, Romanowski, B, Roteli-Martins, CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247–1255. Google Scholar | Crossref | Medline | ISI |
| 22. | Romanowski, B, de Borba, PC, Naud, PS, Roteli-Martins, CM, De Carvalho, NS, Teixeira, JC, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009; 374: 1975–1985. Google Scholar | Crossref | Medline | ISI |
| 23. | De Carvalho, N, Teixeira, J, Roteli-Martins, CM, Naud, P, De Borba, P, Zahaf, T, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010; 28: 6247–6255. Google Scholar | Crossref | Medline |
| 24. | Roteli-Martins, CM, Naud, P, De Borba, P, Teixeira, JC, De Carvalho, NS, Zahaf, T, et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother 2012; 8: 390–397. Google Scholar | Crossref | Medline |
| 25. | Naud, PS, Roteli-Martins, CM, De Carvalho, NS, Teixeira, JC, de Borba, PC, Sanchez, N, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother 2014; 10: 2147–2162. Google Scholar | Crossref | Medline | ISI |
| 26. | Konno, R, Tamura, S, Dobbelaere, K, Yoshikawa, H. Efficacy of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double-blind, randomized, controlled trial. Int J Gynecol Cancer 2010; 20: 404–410. Google Scholar | Crossref | Medline |
| 27. | Konno, R, Tamura, S, Dobbelaere, K, Yoshikawa, H. Efficacy of human papillomavirus type 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double-blind, randomized controlled trial. Int J Gynecol Cancer 2010; 20: 847–855. Google Scholar | Crossref | Medline |
| 28. | Paavonen, J, Jenkins, D, Bosch, FX, Naud, P, Salmeron, J, Wheeler, CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369: 2161–2170. Google Scholar | Crossref | Medline | ISI |
| 29. | Paavonen, J, Naud, P, Salmeron, J, Wheeler, CM, Chow, SN, Apter, D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: 301–314. Google Scholar | Crossref | Medline | ISI |
| 30. | Lehtinen, M, Paavonen, J, Wheeler, CM, Jaisamrarn, U, Garland, SM, Castellsague, X, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13: 89–99. Google Scholar | Crossref | Medline | ISI |
| 31. | Wheeler, CM, Castellsague, X, Garland, SM, Szarewski, A, Paavonen, J, Naud, P, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13: 100–110. Google Scholar | Crossref | Medline |
| 32. | Palmroth, J, Merikukka, M, Paavonen, J, Apter, D, Eriksson, T, Natunen, K, et al. Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination. Int J Cancer 2012; 131: 2832–2838. Google Scholar | Crossref | Medline |
| 33. | Szarewski, A, Poppe, WAJ, Skinner, SR, Wheeler, CM, Paavonen, J, Naud, P, et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV-16/18. Int J Cancer 2012; 131: 106–116. Google Scholar | Crossref | Medline |
| 34. | Apter, D, Wheeler, CM, Paavonen, J, Castellsague, X, Garland, SM, Skinner, SR, et al. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial. Clin Vaccine Immunol 2015; 22: 361–373. Google Scholar | Crossref | Medline |
| 35. | Struyf, F, Colau, B, Wheeler, CM, Naud, P, Garland, S, Quint, W, et al. Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA. Clin Vaccine Immunol 2015; 22: 235–244. Google Scholar | Medline |
| 36. | Herrero, R, Wacholder, S, Rodriguez, AC, Solomon, D, Gonzalez, P, Kreimer, AR, et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov 2011; 1: 408–419. Google Scholar | Crossref | Medline |
| 37. | Kreimer, AR, Rodriguez, AC, Hildesheim, A, Herrero, R, Porras, C, Schiffman, M, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011; 103: 1444–1451. Google Scholar | Crossref | Medline |
| 38. | Rodriguez, AC, Solomon, D, Herrero, R, Hildesheim, A, Gonzalez, P, Wacholder, S, et al. Impact of human papillomavirus vaccination on cervical cytology screening, colposcopy, and treatment. Am J Epidemiol 2013; 178: 752–760. Google Scholar | Crossref | Medline |
| 39. | Hildesheim, A, Wacholder, S, Catteau, G, Struyf, F, Dubin, G, Herrero, R, et al. Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine 2014; 32: 5087–5097. Google Scholar | Crossref | Medline |
| 40. | Hildesheim, A, Gonzalez, P, Kreimer, AR, Wacholder, S, Schussler, J, Rodriguez, AC, et al. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. Am J Obstet Gynecol 2016; 215: 212.e1–15. Google Scholar | Crossref | Medline |
| 41. | Beachler, DC, Kreimer, AR, Schiffman, M, Herrero, R, Wacholder, S, Rodriguez, AC, et al. Multisite HPV16/18 vaccine efficacy against cervical, anal, and oral HPV infection. J Natl Cancer Inst 2016; 108: 1: djv302–djv302. Google Scholar | Crossref | Medline |
| 42. | Skinner, SR, Szarewski, A, Romanowski, B, Garland, SM, Lazcano-Ponce, E, Salmeron, J, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet 2014; 384: 2213–2227. Google Scholar | Crossref | Medline |
| 43. | Wheeler, CM, Skinner, SR, Del Rosario-Raymundo, MR, Garland, SM, Chatterjee, A, Lazcano-Ponce, E, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis 2016; 16: 1154–1168. Google Scholar | Crossref | Medline |
| 44. | Zhu, F-C, Chen, W, Hu, Y-M, Hong, Y, Li, J, Zhang, X, et al. Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18–25 years: results from a randomized controlled trial. Int J Cancer 2014; 135: 2612–2622. Google Scholar | Crossref | Medline |
| 45. | Zhu, FC, Hu, SY, Hong, Y, Hu, YM, Zhang, X, Zhang, YJ, et al. Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18–25 years: event-triggered analysis of a randomized controlled trial. Cancer Med 2017; 6: 12–25. Google Scholar | Crossref | Medline |
| 46. | Villa, LL, Costa, RLR, Petta, CA, Andrade, RP, Ault, KA, Giuliano, AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271–278. Google Scholar | Crossref | Medline | ISI |
| 47. | Villa, LL, Costa, RL, Petta, CA, Andrade, RP, Paavonen, J, Iversen, OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95: 1459–1466. Google Scholar | Crossref | Medline | ISI |
| 48. | Garland, SM, Hernandez-Avila, M, Wheeler, CM, Perez, G, Harper, DM, Leodolter, S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928–1943. Google Scholar | Crossref | Medline | ISI |
| 49. | Future II Study Group . Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis 2007; 196: 1438–1446. Google Scholar | Crossref | Medline |
| 50. | Munoz, N, Manalastas, R, Pitisuttithum, P, Tresukosol, D, Monsonego, J, Ault, K, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet 2009; 373: 1949–1957. Google Scholar | Crossref | Medline | ISI |
| 51. | Castellsague, X, Munoz, N, Pitisuttithum, P, Ferris, D, Monsonego, J, Ault, K, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br J Cancer 2011; 105: 28–37. Google Scholar | Crossref | Medline |
| 52. | Yoshikawa, H, Ebihara, K, Tanaka, Y, Noda, K. Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18–26 years. Cancer Sci 2013; 104: 465–472. Google Scholar | Crossref | Medline |
| 53. | Wei, L, Xie, X, Liu, J, Zhao, Y, Chen, W, Zhao, C, et al. Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: a randomized, placebo-controlled trial with 78-month follow-up. Vaccine 2019; 37(27): 3617–3624. Google Scholar | Crossref | Medline |
| 54. | Yudkin, JS, Lipska, KJ, Montori, VM. The idolatry of the surrogate. BMJ 2011; 343: d7995–d7995. Google Scholar | Crossref | Medline |
| 55. | Tainio, K, Athanasiou, A, Tikkinen, KAO, Aaltonen, R, Cardenas, J, Hernandes, et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. BMJ 2018; 360: k499–k499. Google Scholar | Crossref | Medline |
| 56. | Munoz, N, Kjaer, SK, Sigurdsson, K, Iversen, OE, Hernandez-Avila, M, Wheeler, CM, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010; 102: 325–339. Google Scholar | Crossref | Medline |
| 57. | Pagliusi, SR, Aguado, MT. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004; 23: 569–578. Google Scholar | Crossref | Medline | ISI |
| 58. | Smith, JS, Lindsay, L, Hoots, B, Keys, J, Franceschi, S, Winer, R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007; 121: 621–632. Google Scholar | Crossref | Medline | ISI |
| 59. | Kjaer, SK, Frederiksen, K, Munk, C, Iftner, T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010; 102: 1478–1488. Google Scholar | Crossref | Medline |
| 60. | Harper, DM, DeMars, LR. HPV vaccines – a review of the first decade. Gynecol Oncol 2017; 146: 196–204. Google Scholar | Crossref | Medline |
| 61. | Future II Study Group . Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915–1927. Google Scholar | Crossref | Medline | ISI |
| 62. | Sow, PS, Watson-Jones, D, Kiviat, N, Changalucha, J, Mbaye, KD, Brown, J, et al. Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10–25-year-old HIV-seronegative African girls and young women. J Infect Dis 2013; 207: 1753–1763. Google Scholar | Crossref | Medline |
| 63. | Brown, DR, Kjaer, SK, Sigurdsson, K, Iversen, OE, Hernandez-Avila, M, Wheeler, CM, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis 2009; 199: 926–935. Google Scholar | Crossref | Medline | ISI |
| 64. | Weinberger, DM, Malley, R, Lipsitch, M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011; 378: 1962–1973. Google Scholar | Crossref | Medline | ISI |
| 65. | Public Health England. Cervical Screening: Programme Overview. See https://www.gov.uk/guidance/cervical-screening-programme-overview (2015, last checked 28 Oct 2017). Google Scholar |
| 66. | Force USPST. U.S. Preventive Services Task Force Cervical Cancer Screening. Archived Final Recommendation. See https://www.uspreventiveservicestaskforce.org/Page/Document/Recommendation StatementFinal/cervical-cancer-screening#consider (2013, last checked 26 May 2019). Google Scholar |
| 67. | Eklund, C, Forslund, O, Wallin, KL, Zhou, T, Dillner, J. Network WHOHPL . The 2010 global proficiency study of human papillomavirus genotyping in vaccinology. J Clin Microbiol 2012; 50: 2289–2298. Google Scholar | Crossref | Medline |
| 68. | Dillner, J . The serological response to papillomaviruses. Semin Cancer Biol 1999; 9: 423–430. Google Scholar | Crossref | Medline | ISI |
| 69. | Pollock, KG, Kavanagh, K, Potts, A, Love, J, Cuschieri, K, Cubie, H, et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer 2014; 111: 1824–1830. Google Scholar | Crossref | Medline |
| 70. | Palmer, T, Wallace, L, Pollock, KG, Cuschieri, K, Robertson, C, Kavanagh, K, et al. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12–13 in Scotland: retrospective population study. BMJ 2019; 365: l1161–l1161. Google Scholar | Crossref | Medline |
| 71. | Neville, FG, McEachran, J, Aleman-Diaz, A, Whitehead, R, Cosma, A, Currie, D, et al. Trends in the sexual behaviour of 15-year olds in Scotland: 2002–14. Eur J Public Health 2017; 27: 835–839. Google Scholar | Crossref | Medline |
| 72. | National Statistics. Scottish Cervical Screening Programme Statistics 2017/18. See https://www.isdscotland.org/Health-Topics/Cancer/Publications/2018-09-04/2018-09-04-Cervical-Screening-Report.pdf (2018, last checked 22 Apr 2019). Google Scholar |
| 73. | Wilyman, J . HPV vaccination programs have not been shown to be cost-effective in countries with comprehensive Pap screening and surgery. Infect Agent Cancer 2013; 8: 21–21. Google Scholar | Crossref | Medline |
| 74. | Public Health England. Cervical Screening: Implementation Guide for Primary HPV screening. See https://www.gov.uk/government/publications/cervical-screening-primary-hpv-screening-implementation/cervical-screening-implementation-guide-for-primary-hpv-screening (2019, last checked 29 Mar 2019). Google Scholar |
